Blackard C E, Byar D P, Seal U S, Doe R P
J Urol. 1975 Apr;113(4):517-20. doi: 10.1016/s0022-5347(17)59515-4.
Total 17-OHCS values were determined before and after treatment in 715 patients with all stages of prostatic cancer. The pre-treatment 17-OHCS level was an important variable in predicting survival and appeared to be a better prognostic indicator of death in the first year than the patient's age, treatment or stage of disease. Generally, the higher the initial value of serum 17-OHCS the greater the probability of death in the first year of treatment. There was no preponderance of one type of death over another when patients with initial high and low values were compared.
对715例处于前列腺癌各期的患者在治疗前后测定了17-羟皮质类固醇（17-OHCS）的总量。治疗前的17-OHCS水平是预测生存率的一个重要变量，并且在预测第一年的死亡情况方面似乎比患者的年龄、治疗方式或疾病分期是更好的预后指标。一般来说，血清17-OHCS的初始值越高，治疗第一年死亡的可能性就越大。比较初始值高和低的患者时，并未发现某一种死亡类型占优势。
